Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CADL

HOLDREMOVE

Candel Therapeutics, Inc. · Healthcare · United States · $593M · Avg Vol: $18M/d

58
StockRank
Q
34
V
36
M
77
P/E (TTM)
ROE
-51.2%
D/E
0.4x
Dividend %
AI CONVICTION THESIS

Candel Therapeutics is a highly speculative, clinical-stage biotech company with low quality metrics and no current revenues, failing our Terry Smith quality filter.

COMPANY DESCRIPTION

Candel Therapeutics, Inc. is a clinical-stage biotechnology company developing oncolytic viral immunotherapies for the treatment of various cancers. The company leverages a proprietary oncolytic viral platform designed to selectively destroy cancer cells and stimulate systemic anti-tumor immunity. Candel Therapeutics operates as a niche player in the immuno-oncology space, pursuing novel approaches for difficult-to-treat malignancies.

FINANCIAL SUMMARY

Year20212022202320242025CAGR
Revenue125,000000
EPS-1.91-0.65-1.31-1.74
Shares29M29M47M55M+89.5%
Debt23M23M13M49M29.1%
Equity48M13M66M52M2.9%
Op CF-31M-34M-27M-38M
Inv CF-1M-280,000-16,000-560,000
Fin CF20M-121,00094M56M
Loading...
PRICE (1M)+13.7%
7.537.978.408.849.27May 4May 26Jun 15
SMA 50SMA 200
Close
$8.56
RSI (14)
59.1
52W High
$9.57
From 52W High
0.9%

SCORE BREAKDOWN

Quality
34
ROIC
-31.0%22.4
ROE
-51.2%17.0
GP/Assets
N/A
Op. Margin
0.0%40.6
FCF/Assets
-30.3%9.4
Piotroski
28.8
Int. Cover
-17.0x20.6
D/E Ratio
0.36x39.0
Current Ratio
28.05x97.6
Value
36
P/E (TTM)
N/A
EV/EBITDA
-8.7x79.8
P/FCF
N/A
P/B
4.5x26.8
P/S
N/A
Div Yield
N/A
Momentum
77
52W High %
89%88.1
RS 6M
24%88.8
SMA 50/200
1.25x92.2
EPS Rev 4W
N/A
EPS Rev 12W
N/A
EPS Improve
+122%77.5
Q Growth
N/A

FUNDAMENTALS

Market Cap
$593M
P/E (Forward)
38.9x
Gross Margin
0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CADL are excluded.

TickerCompanyMkt CapStockRankSignal
CADLCandel Therapeutics, Inc.(you)$593M58HOLD
TECXTectonic Therapeutic, Inc.$562M56HOLD
RLMDRelmada Therapeutics, Inc.$760M59HOLD
MDXGMiMedx Group, Inc.$547M65BUY
IPSCCentury Therapeutics, Inc.$430M55HOLD
MGTXMeiraGTx Holdings plc$926M59HOLD
IMMXImmix Biopharma, Inc.$629M48HOLD
CLYMClimb Bio, Inc.$649M46HOLD
OMEROmeros Corporation$807M50HOLD
ANROAlto Neuroscience, Inc.$710M47HOLD

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Candel Therapeutics, Inc. (CADL) — Stock Score Summary

Candel Therapeutics, Inc. (CADL) has a MoatMap StockRank of 58/100 based on Quality (34/100), Value (36/100), and Momentum (77/100) factor scores. The current signal is HOLD. Candel Therapeutics is a highly speculative, clinical-stage biotech company with low quality metrics and no current revenues, failing our Terry Smith quality filter.

Candel Therapeutics, Inc. is a clinical-stage biotechnology company developing oncolytic viral immunotherapies for the treatment of various cancers. The company leverages a proprietary oncolytic viral platform designed to selectively destroy cancer cells and stimulate systemic anti-tumor immunity. Candel Therapeutics operates as a niche player in the immuno-oncology space, pursuing novel approaches for difficult-to-treat malignancies.

Key Financial Metrics

Price$8.56
Market Cap$593M
P/E (Forward)38.91
Price/Book4.54
Return on Equity-51.2%
Return on Invested Capital-31.0%
Debt/Equity35.70
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-38M

Candel Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Candel Therapeutics, Inc.’s (CADL) StockRank?
MoatMap’s StockRank for Candel Therapeutics, Inc. (CADL) is 58/100, with a Hold signal. It is a composite of Quality (34), Value (36), and Momentum (77) factor ranks across MoatMap’s 19,000+ stock universe.
Does Candel Therapeutics, Inc. have an economic moat?
Candel Therapeutics, Inc. (CADL) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Candel Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Candel Therapeutics, Inc. (CADL) is Hold, based on a StockRank of 58/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Candel Therapeutics, Inc. in?
Candel Therapeutics, Inc. (CADL) operates in the Healthcare sector, specifically the Biotechnology industry (United States).